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A number of childhood vaccination programmes have recently introduced
vaccination against Streptococcus pneumoniae, the pneumococcus, a major
cause of pneumonia and meningitis. The pneumococcal conjugate vaccines
(PCVs) that are currently in use only protect against some serotypes of the
bacterium, and there is now strong evidence that those serotypes not
included in the vaccine increase in prevalence among most vaccinated popu-
lations.We present amathematical model for the dynamics of nasopharyngeal
carriage of S. pneumoniae that allows for carriage with multiple serotypes.
The model is used to predict the prevalence of vaccine type (VT) and
non-VT (NVT) serotypes following the introduction of PCV. Parameter
estimates for the model are obtained by maximum likelihood using pre-
vaccination data from The Gambia. The model predicts that low (1, 6A
and 9V) and medium (4, 5, 7F, 14, 18C, 19A and 19F) prevalence serotypes
can be eliminated through vaccination, but that the overall prevalence of
carriage will be reduced only slightly because of an increase in the prevalence
of NVT serotypes. Serotype replacement will be sequential, with high and
medium prevalence NVT serotypes dominating initially, followed by an
increase of serotypes of low prevalence. We examine the impact of a hypo-
thetical vaccine that provides partial protection against all serotypes, and
find that this reduces overall carriage, but is unable to eliminate low or
medium prevalence serotypes.
1. Background
Streptococcus pneumoniae, the pneumococcus, is a common cause of pneumonia,
septicaemia and meningitis. It is also found frequently in the upper respiratory
tract in the absence of any symptoms, a phenomenon known as nasopharyn-
geal carriage. The bacterium has been subclassified into 94 different serotypes
on the basis of the structure of its capsular polysaccharide. Each capsular
polysaccharide induces type-specific antibodies [1].
A seven-valent pneumococcal conjugate vaccine (PCV7) was introduced in
The Gambia as part of the national Expanded Programme of Immunization
in 2009 and was replaced by a 13-valent vaccine (PCV13) in 2011. These vac-
cines protect against disease caused by pneumococci of serotypes represented
in the vaccine (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F
in the case of PCV13), but not against other serotypes.
Results from a pneumococcal vaccine trial conducted in The Gambia, West
Africa, showed that a reduction in the prevalence of nasopharyngeal carriage of
vaccine type (VT) serotypes following vaccination was accompanied by an
& 2013 The Authors. Published by the Royal Society under the terms of the Creative Commons Attribution
License http://creativecommons.org/licenses/by/3.0/, which permits unrestricted use, provided the original
author and source are credited.
increase in non-VT (NVT) serotypes [2]. Similarly, invasive
disease associated with NVT serotypes tends to increase
after the introduction of PCVs. In the USA, for example,
surveillance data from the CDC showed that the incidence
of invasive disease in children under 2 years caused by
non-vaccine serotypes increased from 13 to 19 cases per
100 000/year 4 years after the introduction of PCV7 [3]. The
evidence for serotype replacement in both carriage and inva-
sive disease following vaccination has been reviewed by
Whitney & Moore [4], and recently by Weinberger et al. [5].
In this study, we use a mathematical model to predict the
extent of the serotype replacement in carriage following
the introduction of pneumococcal vaccination in The
Gambia. Parameter estimates for the model are obtained
from data collected before the introduction of PCV in The
Gambia [6]. The model will be validated in due course,
when post PCV surveys of carriage have been conducted.
2. Model
We model the dynamics of S. pneumoniae serotypes determi-
nistically. Specifically, we assume a model of superinfection
along the lines of Nowak & May [7] and Tanaka & Feldman
[8], in which individuals are infected with at most one sero-
type at a time (see appendix for a model in which this
assumption is relaxed). Serotype-specific immunity is incor-
porated into the model by allowing a proportion of infected
individuals to develop lifelong immunity to the serotype
following infection.
In a model with n serotypes, we must keep track of 2n
immune states because an individual can be either immune
or susceptible to each of the serotypes. The model becomes
computationally intractable even for moderate size n—e.g.
for n ¼ 30, there are over 1 billion states. To simplify
the model, we group serotypes into classes (i ¼ 1,. . .,m);
within a particular class, all ni serotypes are acquired and
cleared at the same rate and are of the same type (i.e. VT
or NVT). As all serotypes within a class are equivalent,
an individual’s immune state can be followed by tracking
the total number of serotypes within each class to which
the individual has immunity. This simplification can sub-
stantially reduce the number of possible immune states.
For example, with m ¼ 6 classes and five serotypes in each
class, there are six states for each class (immunity to 0, 1, 2,
3, 4 or 5 serotypes) and a total of 66 ¼ 46 656 possible
immune states.
To this end, we denote an immune state by h ¼ (h1,
h2,. . .,hm), where hi (0  hi  ni) is the number of serotypes
in class i to which immunity has been acquired. The follow-
ing differential equations describe the dynamics of xh and
yðiÞh , which represent, respectively, the proportions of non-
carriers and carriers of a serotype in class i with immune
state h among the total population. We use the notation
hi2 ¼ (h1,. . .,hi 2 1,. . .,hm) to represent a state where there is
immunity to one fewer serotype in class i than there is for
state h. We also define yðiÞ ¼Ph yðiÞh to be the proportion of
carriers of serotypes in class i regardless of immune state.
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In these equations, p is the proportion who become
immune after carriage (this is assumed to be the same for ser-
otypes in all classes), ni are per capita rates of clearance, l
ðiÞ
h is
the force of infection owing to serotypes in class i among non-
carriers in immune state h and g is the reduction in the rate of
acquisition among carriers, relative to non-carriers. Individ-
uals are born at a per capita rate m, and die at the same rate,
irrespective of their carriage status or immune state. The
births are divided among the immune states, and the pro-
portion born into immune state h is dh. In the absence of
vaccination, individuals are born fully susceptible to all sero-
types (i.e. we neglect any maternal immunity) so that dh ¼ 1
when h ¼ (0,. . .,0) and zero otherwise. After vaccine intro-
duction, we assume that a fraction, f, of the vaccinated
children have immunity to VT serotypes at birth, while the
remainder are born susceptible to all serotypes.
The per capita rate at which non-carriers in immune state
h acquire serotypes of class i (i.e. the force of infection
due to class i serotypes among non-carriers in state h) is
l
ðiÞ
h ¼ bið1 hi/niÞyðiÞ, where bi is the transmission parameter
(per capita contact rate), and (12 hi/ni) represents theproportion
of serotypes in class i to which non-carriers are susceptible.
We have described the model in terms of the proportion
of the population with immune state h who are carriers of a
class i serotype. Because all serotypes in a prevalence class
have the same contact and clearance rates, the proportion of
the population with immune state h that carry a particular
class i serotype is yðiÞh /ni, and across all immune states the
proportion of carriers is yðiÞ/ni. Furthermore, the model that
has been described is equivalent to modelling the dynamics
of all serotypes explicitly, in a model with n ¼Pni serotypes
and n classes, provided that the parameters and initial con-
ditions for the serotypes are the same in the two models.
For example, a model with two serotypes and two classes
is equivalent to a model with two serotypes in a single
class, if in the model with two classes, both serotypes have
the same contact and clearance rates, and initial prevalence.
The advantage of formulating the model as above is that it
substantially reduces the amount of computation.
2.1. Fitting the model
We parametrized the model using data collected as part of a
baseline study for a community vaccine trial in the Sibanor
region of The Gambia. In this study, nasopharyngeal swabs
were collected from 170 subjects, of all ages, every two
weeks for 50 weeks. A full description of the study is given
in Hill et al. [6].
The model was fitted to data on the number of transitions
between carriage states, where the carriage state is defined
as either the absence of carriage or the presence of a parti-
cular serotype. Samples were excluded from the analysis
whenever more than one serotype was isolated (the percen-
tages of swabs with two and three serotypes were 2.95%
and 0.04%, respectively).
Both VT and NVT serotypes were grouped according
to their prevalence (low ,0.5%, medium 0.5–2% or high
.2%) in pre-vaccination data from The Gambia, which is
rsif.royalsocietypublishing.org
JR
SocInterface
10:20130786
2
similar to that found in other parts of Africa [9,10]. Serotype
prevalence is a function of contact (b) and clearance (n) rates,
both of which are themselves positively correlated [10]; hence
we expect the rates of contact and clearance to be similar
among serotypes of similar prevalence.
We used the rates of transition implied by the model
at equilibrium to define a likelihood in terms of probabilities
of transition between carriage states in consecutive naso-
pharyngeal swabs. Parameter estimates were obtained by
maximizing the likelihood using a Nelder–Mead algorithm
and Wald-type confidence intervals are presented. The meth-
odology used to fit the model is described in more detail in
the appendix.
3. Results
3.1. Model projections
The model predicts that the prevalence of carriage of VT
serotypes will decline significantly from 20.1% before vacci-
nation to 3.0% 10 years after vaccine introduction assuming
full vaccine coverage, and 4.8% and 6.5% for 80% and 60%
coverage, respectively (figure 1); low (1, 6A and 9V) and
medium prevalence VT serotypes (4, 5, 7F, 14, 19A, 18C
and 19F) will be driven to extinction so that only high preva-
lence VT serotypes (3, 6B and 23F) will continue to circulate
in the population. The decline in VT serotypes will be coun-
tered by an increase in NVT serotypes from 22.3% to 36.1%,
34.8% and 33.5%, assuming 100%, 80% and 60% coverage,
respectively, so that the net effect over 10 years is a small
reduction in overall carriage—e.g. from 42.4 to 39.1% for
full vaccine coverage. Serotype replacement will initially be
dominated by serotypes from the high and medium preva-
lence classes, but will be followed by an expansion of low
prevalence serotypes. During the first 2 years after vaccine
introduction, assuming full coverage, low prevalence NVT
serotypes will each increase 0.05% per year, whereas high
prevalence NVT will increase by 0.36% per year. By contrast,
in the following 3 years, low prevalence NVT serotypes will
increase by 0.10% per year but high prevalence serotypes
will decrease by 0.25% per year (see also figure 1).
3.2. Model fit
Parameter estimates are given in table 1. The model fits the
Gambian pre-vaccination data well. The prevalence of car-
riage predicted by the model (VT and NVT combined) was
similar to that observed: the predicted prevalence for low,
medium and high prevalence serotypes was 0.056 (observed
0.058), 0.187 (observed 0.190) and 0.181 (observed 0.221),
respectively, where the observed prevalence corresponds to
the average prevalence from swabs collected during the
study (N.B. this is less than the proportion infected at any-
time in the study—85% adults, 97% children—reported in
[6]). The predicted probability of transition from carriage of
one serotype to another was also generally close to the
observed probability (table 2).
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Figure 1. The prevalence of pneumococcal serotypes before vaccination (a), and the prevalence of carriage after the introduction of vaccination at three different
levels of coverage (b).
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3.3. Alternative vaccines
The model was used to explore the effect on pneumococcal
carriage of four hypothetical vaccines that target different com-
binations of serotypes: (i) PCV13 and low prevalence serotypes;
(ii) PCV13 and medium prevalence seroytpes; (iii) PCV13 and
high prevalence seroytpes and (iv) all serotypes. We assumed
100% vaccine coverage and 50% vaccine efficacy against each
serotype included in the vaccine. For vaccines 1–3, low and
medium prevalence VT serotypes were eliminated, but
there was serotype replacement, and therefore only a limited
reduction in the prevalence of overall carriage. By definition,
there can be no serotype replacement for vaccine 4, and there
was consequently a significant reduction in carriage from 42.4
to 24.8%; however, low and medium prevalence serotypes
were not eliminated by this vaccine (figure 2).
3.4. Sensitivity analyses
The model was fitted by grouping serotypes into three preva-
lence classes, assuming that all serotypes in a class have the
same contact and clearance rate. To explore the effect of relax-
ing this assumption, we compared two six-serotypemodels. In
the first model, all serotypes have different contact rates,
whereas in the second model we grouped serotypes into low,
medium and high prevalence classes, of two serotypes each,
where the contact rate for both serotypes that share a class
was the average of the contact rates used in the first model.
We found that the dynamics of serotypes was similar in the
two models (see electronic supplementary material, figure S1).
We used a model that allows for simultaneous carriage of
two serotypes to investigate the effect of co-infection on ser-
otype replacement (see appendix for a description of the
model). The model was used to simulate pneumococcal car-
riage over a 2-year period (a shorter period was used because
simulation of the co-infection model was computer inten-
sive). For the simulation, we assumed full vaccine coverage
and used the parameter values that were estimated for the
superinfection model (table 1). We found that co-infection
does not preclude serotype replacement (see electronic
supplementary material, figure S2). In the first 2 years follow-
ing vaccination, carriage of VT serotypes declined from 23.1
to 14.8%, and carriage of VT serotypes increased from 27.4
to 33.7%. The serotype replacement was slightly less than pre-
dicted under the superinfection model over the same period,
where VT serotypes declined from 20.8 to 10.6%, and NVT
serotypes increased from 22.3 to 30.9%.
Table 1. Description of variables and parameters.
descriptiona variable/parameter estimate (95% CI)
proportion of population with immune history h and carriers of class i serotypes yðiÞh n.a.
proportion of population carriers of class i serotypes y(i) n.a.
proportion of population with immune history h and non-carriers xh n.a.
contact rate for low transmission serotypes among non-carriers b1 0.085 (0.066,0.109)
contact rate for medium transmission serotypes among non-carriers b2 0.090 (0.064,0.128)
contact rate for high transmission serotypes among non-carriers b3 0.143 (0.071,0.289)
factor by which the rate of acquisition is reduced for carriers g 0.630 (0.407,0.975)
proportion that develop immunity after carriage p 0.051 (0.032,0.082)
rate of carriage clearance for low transmission serotypes n1 0.049 (0.035,0.068)
rate of carriage clearance for medium transmission serotypes n2 0.039 (0.031,0.049)
rate of carriage clearance for high transmission serotypes n3 0.031 (0.025,0.038)
per capita rate of births and deaths m 0.00011b
vaccine efﬁcacy f 0.5c
aRates per capita per day.
bBased on an estimated crude birth rate in The Gambia of 40 per 1000 per year.
cEstimated for PCV7 in [11].
Table 2. Loss and acquisition of serotypes in consecutive nasopharyngeal swabs. Nasopharyngeal swabs were taken every two weeks over 50 weeks, and
serotypes are grouped as low, medium and high prevalence. The total number of transitions is reported, together with the observed probability of transition,
and the probability predicted by the model (obs., obseved/pred., predicted).
from: to: no carriage (obs./pred.) low (obs./pred.) medium (obs./pred.) high (obs./pred.) Na
no carriage 40 (0.037/0.038) 123 (0.114/0.114) 111 (0.103/0.100) 1075
low 50 (0.472/0.409) 9 (0.085/0.029) 12 (0.113/0.090) 15 (0.142/0.081) 106
medium 119 (0.317/0.354) 15 (0.040/0.029) 40 (0.107/0.087) 34 (0.091/0.085) 375
high 119 (0.285/0.304) 14 (0.034/0.029) 40 (0.096/0.095) 28 (0.067/0.087) 417
aTotal number of pairs of consecutive swabs.
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4. Discussion
Projections from themodel described in this paper suggest that
PCV13 vaccination will lead to the elimination of low (1, 6A
and 9V) and medium (4, 5, 7F, 14, 18C, 19A and 19F) preva-
lence VT serotypes and substantially reduce carriage of high
prevalence serotypes (3, 6B and 23F) in The Gambia. However,
the model predicts only a small reduction in the overall preva-
lence of carriage because the decrease in VT serotypes is
counteracted by an increase in NVT serotypes. Initially, sero-
type replacement will be dominated by high prevalence NVT
serotypes, but this will be followed by replacement with low
prevalence serotypes as the population accrues immunity to
the high prevalence NVT serotypes.
These predictions are broadly in agreement with studies
that have compared the prevalence of carriage before and
after the introduction of PCV vaccination, although there are
as yet limited data on the impact of PCV13. Flasche et al.
[12], for example, compared pre-vaccination data (2001/2002)
with post-vaccination data (2008/2009) obtained from children
under 5 years and their household contacts in a study con-
ducted in the UK. The odds of VT carriage decreased by 93%
post-vaccination, and serotypes 4 and 9V were not identified
in any swabs (n ¼ 382) after vaccination. NVT serotypes
increased in this study so that there was no change in the over-
all level of carriage after vaccine introduction. Similar findings
have been reported from pre- and post-vaccination carriage
studies conducted elsewhere and are reviewed by Weinberger
et al. [5]. Surveillance data are not yet available from
The Gambia following the introduction of PCV13. However,
Gambian children who had received PCV9 in the course
of a randomized trial of this vaccine were more likely to
carry NVT serotypes than control children and less likely
to carry VT serotoypes [13].
Mixed results were obtained in a cluster randomized trial
conducted in 21 Gambian villages. In this study, 11 villages
were fully vaccinated with PCV7, and 10 control villages
were partially vaccinated: only children 2–30 months and
those born during the trial were vaccinated. The prevalence
of VT serotypes was lower among vaccinated than control
communities, but the prevalence of NVT serotypes was simi-
lar in the two arms of the trial [14,15]. In a comparison of
prevalence at baseline and at six months post-vaccination,
both VT and NVT serotypes decreased after vaccination,
except among children aged 2–5 years where the prevalence
of NVT serotypes increased.
In fitting the model to pre-vaccination data, we estimated
that the probability of acquiring immunity after a single episode
of carriage is 5% or, assuming immunity is acquired gradually,
that the rate of acquisition of a serotype is reduced by 5% after
each episode of carriage. The data are consistent with this find-
ing since multiple episodes of carriage of the same serotype
occurred frequently, particularly among children. For example,
serotype 6B was carried on more than one occasion in 52% of
children under 5 years, and some children carried serotype 6B
up to six times during the year of follow up. This result is
also supported by another Gambian study which found
that only carriage of pneumococci of serotype 14 provided
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Figure 2. The prevalence of carriage after the introduction of four hypothetical vaccines. The vaccines protect against either low, medium or high prevlence
serotypes as well as serotypes included in PCV13, or all serotypes. The vaccine efficacy against each serotype is assumed to be 50%, and coverage is 100%.
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significant protection against subsequent reinfection with
the same serotype, perhaps because this serotype induces a
stronger immune response than other serotypes [16,17].
We also quantified the degree of competition between
serotypes in the nasopharynx using the parameter g in the
model: for g, 1, the serotype resident in the nasopharynx
has a competitive advantage, while for g. 1 the advantage
goes to the establishing serotype. We estimated g ¼ 0.63,
that is the rate of serotype acquisition is 37% lower among
individuals that already carry a serotype compared with
non-carriers. Auranen et al. [18] also found that the rate
of acquisition was reduced for carriers compared with
non-carriers, although the estimated reduction was much
larger (91%) in this case. In a longitudinal study of Kenyan
children, the reduction varied by serotype, but was gene-
rally less, with a maximum reduction of 52% observed for
serotype 19F [10].
The relationship between carriage and disease is well
established [19], and it is probable that the acquisition of
S. pneumoniae in the naspharynx is a necessary step for pro-
gression to disease. Pneumococcal serotypes vary in their
ability to cause disease [12,20], and PCVs target the most viru-
lent serotypes. Surveillance data from countries that have
introduced pneumococcal vaccination have shown that these
vaccines are able to reduce the incidence of disease despite ser-
otype replacement [4]. In The Gambia, serotypes targeted by
PCV13 are associated with three quarters of the cases of pneu-
mococcal disease [21], but their prevalence in the nasopharynx
is comparatively low (e.g. 20% in our data). The vaccine is
therefore also expected to reduce disease in The Gambia.
Surveillance for pneumococcal disease post PCV is cur-
rently underway in The Gambia, and further carriage
studies will be conducted in due course. The accuracy of
the model can only be fully assessed once these data
become available. If the model can predict carriage post
PCV in The Gambia, then the model could be used in other
settings where the prevalence of carriage and composition
of serotypes is different. Alternatively, the model might be
used to investigate different vaccines, such as the protein vac-
cine that is currently being developed, which is expected to
protect against all serotypes. We have explored scenarios
involving alternative PCV vaccines, and our results suggest
that carriage can be reduced by vaccines that provide partial
protection against all serotypes. Interestingly, the model also
predicts that low prevalence serotypes could persist in this
situation. Intuitively this is because a vaccine that reduces
overall carriage, will also reduce competition between sero-
types in the nasopharynx that would otherwise drive low
prevalence serotypes to extinction.
The model assumes that naturally acquired immunity is
serotype-specific. The success of serotype-specific pneumo-
coccal vaccines (polysaccharide and conjugate) supports the
view that anticapsular antibodies can protect against invasive
pneumococcal disease and carriage. The observation that
anticapsular IgG is produced in response to pneumococcal
carriage suggests that serotype-specific immunity can be
acquired through carriage [22], and mathematical models of
superinfection predict that serotype-specific immunity is
required to allow coexistence of competing strains [8]. There
is, therefore, substantial evidence in support of serotype-
specific immunity. However, immunity may also be acquired
in other ways. Possible mechanisms include antibodies or
cellular response to non-capsular antigens. Lipsitch et al.
[23] argue that the similar age distribution of invasive pneu-
mococcal disease across serotypes is indicative of a non-
capsule-specific immune response. The model presented
here does not incorporate such an immune response. How-
ever, if a similar level of non-specific immunity can be
induced by pneumococci of all serotypes, this should
remain approximately constant over time in the population
because vaccination has only a modest effect on the overall
prevalence of carriage. It may therefore be unnecessary to
model non-specific immunity in this setting.
Other models of pneumococcal carriage have been devel-
oped, and importantly, serotype replacement is predicted by
all models alike. These models consider a limited number
of serotypes [24] or model VT and NVT carriage without
considering the dynamics of individual serotypes [25,26].
A recent simulation study by Cobey & Lipsitch [27] includes
multiple serotypes, but this model was not fitted to data. By
contrast, we propose a multi-serotype model that we fit to
data and use to make predictions about the impact
of PCV13 in the Gambian setting. In another recent study,
Nurhonen et al. [28] fitted a micro-simulation model to car-
riage data from Finland. Their model is different in
structure and is used in a different context, but they also pre-
dict that VT serotypes can be eliminated, and they predict a
similar degree of serotype replacement.
The ecology of bacterial species within the nasopharynx
is complex. Not only are there interactions between the
94 serotypes of S. pneumoniae but interactions may also exist
between the different bacterial species that inhabit this
ecosystem [29]. Mathematical models can potentially pro-
vide an important tool to help understand this complexity,
particularly in the context of interventions, for example
vaccination, that may act to disrupt existing equilibria.
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Appendix A
A.1. Likelihood
An individual is in one of n þ 1 states corresponding to no
carriage or carriage of one of the n serotypes, we represent
rates of transition between states by a matrix, Q, with
elements qr,s (r, s ¼ 1,. . .,n þ 1).
The transition matrix consists of component matrices Qi,j
with dimensions ni  nj (i, j ¼ 0, 1, 2,. . .,m) that represent
transitions from a state in prevalence class i to a state in
class j, where we define the class i ¼ 0 to be the non-carrier
state so that n0 ¼ 1.
Q0;0 Q0;1    Q0;m
Q1;0 Q1;1    Q1;m
..
. ..
. . .
. ..
.
Qm;0 Qm;1    Qm;m
0
BBBBB@
1
CCCCCA:
We assume that the system is at equilibrium prior to the
introduction of vaccination so that the rates of transition
remain constant over time. The elements of Qi,j are identical
and given below, except where they are on the diagonal of
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Q, in which case they are defined as Ps=r qr;s so that the
rows of Q sum to zero [30].
ni i= 0; j ¼ 0;
bjyðjÞ
nj
P
h xhð1 hj/njÞ
x
i ¼ 0; j= 0;
gbjyð jÞ
nj
P
h y
ðiÞ
h ð1 hj/njÞ
yðiÞ
i; j . 0 and i= j
and
gbiyðiÞ
ni
P
h y
ðiÞ
h ð1 ðhi þ 1Þ/niÞ
yðiÞ
i; j . 0 and i ¼ j
where xh and y
ðiÞ
h are respectively the equilibrium proportions
of non-carriers and carriers of serotypes in class i and
immune state h. The first rate represents serotype clearance
and the remaining rates are for serotype acquisition. The rate
at which a non-carrier acquires a particular serotype in class j
is the product of two terms: the rate at which the individual
comes into contact with class j carriers of the serotype
bjyð jÞ/nj, and the probability that that they are susceptibleP
h xhð1 hj/njÞ/x. Rates of acquisition for carriers are
similarly defined, except that the rate is reduced by a factor g.
Define P(t) as the matrix of transition probabilities associ-
ated with Q for an interval of length t. Using matrix notation,
the forward equations imply that
d
dt
PðtÞ ¼ PðtÞQ:
Given P(0) ¼ I, the identity matrix, the solution to this
equation is
PðtÞ ¼ expðQtÞ
¼ Bdiagðexpðl1tÞ . . . expðlnþ1tÞÞB1;
where l1,. . .,ln þ 1 are distinct eigenvalues of Q and the col-
umns of B are the associated eigenvectors (see [30] for
further details).
Let or,s denote the observed number of transitions bet-
ween r and s over the course of the study (50 weeks), and
pr,s the corresponding element of P, then assuming a
Markov model the log likelihood is
lðb;g; p; nÞ ¼
X
r;s
o r;s logð pr;sÞ:
A.2. Model of co-infection
The original model does not allow for co-infection: it is
assumed that a newly acquired serotype immediately replaces
any existing serotype. Here, we extend the model to incorpor-
ate simultaneous carriage of two serotypes. In this model, yðiÞh
is the population proportion that carry a single serotype in
class i, and zði;jÞh is the proportion that carry two serotypes
from either the same i¼ j or different transmission classes i= j.
dxh
dt
¼ mdh þ ð1 pÞ
X
i
niy
ðiÞ
h þ p
X
i
niy
ðiÞ
hi
 mþ
X
i
l
ðiÞ
h
 !
xh;
dyðiÞh
dt
¼ lðiÞh xh þ ð1 pÞ
X
j=i
njz
ði;jÞ
h þ 2nizði;iÞh
0
@
1
A
þ p
X
j=i
njz
ði;jÞ
hj þ 2niz
ði;iÞ
hi
0
@
1
A mþ ni þ gX
j
l
ðj;iÞ
h
0
@
1
AyðiÞh ;
and
dzði;jÞh
dt
¼ gðl
ði;jÞ
h y
ð jÞ
h þ lð j;iÞh yðiÞh Þ  ðmþ ni þ njÞzði;jÞh i= j
gl
ði;iÞ
h y
ðiÞ
h  ðmþ 2niÞzði;iÞh i ¼ j:
(
We assume that co-carriers are equally likely to transmit
either serotype; the force of infection due to class i serotypes
among non-carriers in state h is then
l
ðiÞ
h ¼ bi 1
hi
ni
 
yðiÞ þ zði;iÞ þ 1
2
X
k=i
zði;kÞ
 !
:
The force of infection due to class i serotypes among
carriers of a class j serotype in state h is
l
ði;jÞ
h ¼
bi 1
hi þ 1
ni
 
yðiÞ þ zði;iÞ þ 1
2
X
k=i
zði;kÞ
 !
i ¼ j
bi 1
hi
ni
 
yðiÞ þ zði;iÞ þ 1
2
X
k=i
zði;kÞ
 !
j= i:
8>>><
>>>:
All other parameters are defined as in the original model.
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